相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer
Edurne Arriola et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts
Takahito Nakahara et al.
CANCER RESEARCH (2007)
Distinct ErbB-2-coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles
Babette Schade et al.
CANCER RESEARCH (2007)
Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells
S. C. Pero et al.
BRITISH JOURNAL OF CANCER (2007)
Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers
S-F Chin et al.
ONCOGENE (2007)
Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients
A. R. Hinnis et al.
BRITISH JOURNAL OF CANCER (2007)
Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation
Edurne Arriola et al.
LABORATORY INVESTIGATION (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A comprehensive analysis of common copy-number variations in the human genome
Kendy K. Wong et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Richard M. Neve et al.
CANCER CELL (2006)
Novel patterns of genome rearrangement and their association with survival in breast cancer
James Hicks et al.
GENOME RESEARCH (2006)
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
Koei Chin et al.
CANCER CELL (2006)
Global variation in copy number in the human genome
Richard Redon et al.
NATURE (2006)
Predictive value of HER-2 and Topoisomerase IIα in response to primary doxorubicin in breast cancer
Edurne Arriola et al.
EUROPEAN JOURNAL OF CANCER (2006)
The SWI/SNF chromatin remodeling subunit BAF57 is a critical regulator of estrogen receptor function in breast cancer cells
Juana M. Garcia-Pedrero et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer
Kyeongmee Park et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes
Jessica Kao et al.
GENES CHROMOSOMES & CANCER (2006)
Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer:: Scandinavian Breast Group Trial 9401
Minna Tanner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
HER2 and responsiveness of breast cancer to adjuvant chemotherapy
KI Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
被撤回的出版物: Oncogenic activity of Cdc6 through repression of the INK4/ARF locus (Retracted article. See vol. 547, pg. 246, 2017)
S Gonzalez et al.
NATURE (2006)
Regulation of survivin by ErbB2 signaling: Therapeutic implications for ErbB2-overexpressing breast cancers
WL Xia et al.
CANCER RESEARCH (2006)
A multiplex PCR predictor for aCGH success of FFPE samples
EH van Beers et al.
BRITISH JOURNAL OF CANCER (2006)
Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:: Danish Breast Cancer Cooperative Group
AS Knoop et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phosphorylation of PEA-15 switches its binding specificity from ERK/MAPK to FADD
H Renganathan et al.
BIOCHEMICAL JOURNAL (2005)
Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity
JS Reis et al.
JOURNAL OF PATHOLOGY (2005)
It's about time: Scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells
RL Bevins et al.
CANCER RESEARCH (2005)
The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study
DG Hicks et al.
HUMAN PATHOLOGY (2005)
Genomic and expression profiling of chromosome 17 in breast cancer reveals complex patterns of alterations and novel candidate genes
B Orsetti et al.
CANCER RESEARCH (2004)
Oncogene addiction: Sometimes a temporary slavery
J Jonkers et al.
CANCER CELL (2004)
Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer
P Kauraniemi et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Metastatic Lymph Node 51, a novel nucleo-cytoplasmic protein overexpressed in breast cancer
S Degot et al.
ONCOGENE (2002)
Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution
H Buerger et al.
JOURNAL OF PATHOLOGY (2001)
Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays
SA Bustin
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2000)
Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer
TAH Jarvinen et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
分享论文
